
To test feasibility of randomization to radical prostatectomy plus pelvic lymphadenectomy (RP) in addition to standard‐of‐care (SOC) systemic therapy in men with newly diagnosed oligo‐metastatic prostate cancer. A prospective, randomized, non‐blinded, feasibility clinical trial with an embedded QuinteT Recruitment Intervention (QRI) to optimize recruitment was conducted in nine tertiary‐care nationwide centers undertaking high‐volume robotic surgery. We aimed to randomize 50 men with synchronous oligo‐metastatic prostate cancer within an 18‐month recruitment period to SOC systemic therapy versus SOC plus RP (intervention arm).The main outcome measures were: ability to randomize participants, optimized by a QRI. EQ‐5D‐5L questionnaires to capture quality‐of‐life (QOL) data at baseline and three months post‐randomization...
Like
Save
Share